1. Home
  2. CACC vs ERAS Comparison

CACC vs ERAS Comparison

Compare CACC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Acceptance Corporation

CACC

Credit Acceptance Corporation

SELL

Current Price

$490.50

Market Cap

5.6B

Sector

Finance

ML Signal

SELL

Logo Erasca Inc.

ERAS

Erasca Inc.

SELL

Current Price

$15.11

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CACC
ERAS
Founded
1972
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.3B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
CACC
ERAS
Price
$490.50
$15.11
Analyst Decision
Hold
Buy
Analyst Count
3
9
Target Price
★ $556.67
$24.11
AVG Volume (30 Days)
105.6K
★ 4.7M
Earning Date
10-29-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 83.00
36.23
EPS
★ 19.92
N/A
Revenue
★ $2,317,200,000.00
N/A
Revenue This Year
$91.39
N/A
Revenue Next Year
$6.82
N/A
P/E Ratio
$25.34
★ N/A
Revenue Growth
★ 7.16
N/A
52 Week Low
$405.00
$2.71
52 Week High
$668.86
$24.28

Technical Indicators

Market Signals
Indicator
CACC
ERAS
Relative Strength Index (RSI) 40.90 50.15
Support Level $461.55 $13.18
Resistance Level $529.95 $15.71
Average True Range (ATR) 23.89 1.23
MACD -0.90 0.15
Stochastic Oscillator 28.36 46.34

Price Performance

Historical Comparison
CACC
ERAS

About CACC Credit Acceptance Corporation

Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: